Saturday 17 October 2026
Export BCLI’s income statement to Excel — free account
Brainstorm Cell Therapeutics Inc.
BCLI Healthcare Biotechnology
In the quarter to June 2026, EPS fell 2.94%, free cash flow grew 74.4% and total debt rose 1,148.5%, each against the same quarter a year earlier.
0.78
0.02
−2.50%
Follow BCLI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
157.76% | 116.14% | 103.65% | 119.20% | |
| (637.06%) | (722.28%) | (442.44%) | (627.43%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
131.75% | 98.49% | 84.08% | 88.29% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.66) | (0.75) | (0.60) | (0.37) | |
Free Cash Flow |
(7.28) | (6.97) | (6.66) | (4.06) | |
| Other line items | |||||
Cash ROIC |
95.99% | 77.59% | 68.95% | 39.33% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.67 | 0.68 | 0.70 | 0.39 | |
Depreciation/Fixed assets |
0.72 | 0.85 | 0.93 | 1.18 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.66) | (0.75) | (0.60) | (0.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates